Physician profile
Debbie Lo
NPI 1932422698
$5,534.19
in general payments reported to CMS, 2019-2025
36 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,038 · 2022: $1,099 · 2023: $782 · 2024: $446 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $833.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $729.44 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $479.34 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $436.82 | 2021-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $428.02 | 2021-2025 | |
| Novo Nordisk INC | $383.01 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $268.37 | 2021-2025 | |
| Lilly USA, LLC | $227.00 | 2021-2025 | Zepbound, Mounjaro |
| Radius Health, INC. | $183.47 | 2021-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.23 | 2022-2025 | Xifaxan, Trulance |
| Amgen INC. | $160.92 | 2021-2025 | Prolia, Prolia, Evenity |
| Biohaven Pharmaceuticals, INC. | $144.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $137.65 | 2022-2023 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $120.03 | 2021-2025 | Kerendia |
| Astellas Pharma US INC | $113.49 | 2023-2025 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $90.67 | 2021-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $60.33 | 2021 | |
| Seqirus USA INC | $57.82 | 2021-2025 | Flucelvax, Fluad |
| Ars Pharmaceuticals Operations, INC. | $50.31 | 2025 | Neffy |
| Biohaven Pharmaceutical Holding Company LTD. | $45.15 | 2022 | |
| Amarin Pharma, INC. | $43.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.82 | 2021-2022 | |
| Sanofi Pasteur INC. | $39.31 | 2022-2025 | |
| Boston Scientific Corporation | $39.03 | 2021-2025 | Watchman Flx |
| Therapeuticsmd, INC. | $32.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.15 | 2021 | |
| Exact Sciences Corporation | $28.57 | 2025 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $19.73 | 2021 | |
| Merck Sharp & Dohme LLC | $19.73 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.09 | 2021 | |
| Esperion Therapeutics, INC. | $16.21 | 2021 | |
| Eisai INC. | $15.90 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.00 | 2023 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $14.83 | 2021 | |
| Cranial Technologies, INC | $14.57 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.